# Adversarial verification verdict — syringoma.md

## 1. DOSE LEAK
None. Full-file digit scan (`grep -o '[0-9]'`) returns only "12" from "12th ed." in the
Sources line. No mg / mg-m2 / AUC / Gy / % / numbered-schedule anywhere.

## 2. UNGROUNDED CLAIMS
None flagged as a problem — every specific claim in the body is explicitly self-labeled inline
as "(general oncology standard, not from DeVita's section on this disease)" rather than being
passed off as DeVita-sourced. Spot-checked the individual claims for plausibility since DeVita
doesn't cover them:
- Ablative CO2 laser, electrodesiccation/electrocautery, dermabrasion, TCA chemical destruction
  for cosmetic syringoma treatment — standard, uncontroversial dermatology management, no
  numbers attached.
- Association of eruptive/widespread syringomatosis with Down syndrome / metabolic-endocrine
  triggers — real, well-established dermatologic association, stated qualitatively only (no
  prevalence %, no specific endocrinopathy list beyond "e.g.").
- Differential list for an atypical/indurated lesion (MAC, morpheaform BCC, desmoplastic
  trichoepithelioma) — matches DeVita line 226348 almost verbatim (desmoplastic
  trichoepithelioma, benign syringoma, morpheaform BCC all appear in that differential list).
No specific regimen, trial, or statistic is asserted anywhere in the file.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology,
12th ed." — name only, no page numbers. Correct.

## 4. DeVita grounding check (independent grep)
`grep -in "syringoma" devita.txt` → 2 hits, matching the draft agent's report exactly:
- Line 226277: "malignant syringoma" listed as a historical synonym for microcystic adnexal
  carcinoma (MAC).
- Line 226348: "benign syringoma" listed in MAC's histologic differential diagnosis.
No dedicated DeVita section on benign syringoma exists. The sidecar's grounding note accurately
represents this (does not overclaim DeVita coverage), and only the MAC-differential distinction
in the Monitoring section is actually traceable to DeVita text.

## VERDICT: CLEAN (ready for R1)

No dose leak, no fabricated-as-DeVita claims (all non-DeVita content is honestly disclaimed
inline), citation format correct, and the one DeVita-grounded point (benign syringoma vs. MAC
differential) is verified against the source text.
